Kazia Therapeutics Limited American Depositary Shares
Compare this stock
KZIA Stock Report Card
$
31%
Performance
Score:
10/100
KZIA returned -32.94% in the last 12 months. Based on SPY's performance of -21.14%, its performance is below average giving it a score of 10 of 100.
Sentiment
Score:
69/100
KZIA had a bullish sentiment score of 69.48% across Twitter and StockTwits over the last 12 months. It had an average of 19.88 posts, 9.81 comments, and 46.23 likes per day.
Technicals
Score:
14/100
KZIA receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Profit
Score:
25/100
Out of the last 20 quarters, KZIA has had 6 profitable quarters and has increased their profits year over year on 3 of them.
Volatility
Score:
55/100
KZIA has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.
Kazia Therapeutics Limited American Depositary Shares Summary
Nasdaq / KZIA
Healthcare
Biotechnology
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
KZIA scored poorly on our reportcard. Here are some similar companies and how they performed.
